探讨Dupilumab治疗特应性皮炎患者的皮肤病生活质量指数、湿疹面积和严重程度指数、睡眠数值评定量表和瘙痒数值评定量量表之间的关系。

IF 4 3区 医学 Q1 DERMATOLOGY
Dermatitis Pub Date : 2023-09-01 Epub Date: 2023-01-19 DOI:10.1089/derm.2022.0031
Filomena Russo, Vittoria Cioppa, Alessandra Cartocci, Ernesto De Piano, Paolo Taddeucci, Laura Lazzeri, Francesco Santi, Pietro Rubegni
{"title":"探讨Dupilumab治疗特应性皮炎患者的皮肤病生活质量指数、湿疹面积和严重程度指数、睡眠数值评定量表和瘙痒数值评定量量表之间的关系。","authors":"Filomena Russo,&nbsp;Vittoria Cioppa,&nbsp;Alessandra Cartocci,&nbsp;Ernesto De Piano,&nbsp;Paolo Taddeucci,&nbsp;Laura Lazzeri,&nbsp;Francesco Santi,&nbsp;Pietro Rubegni","doi":"10.1089/derm.2022.0031","DOIUrl":null,"url":null,"abstract":"<p><p><b><i><u>Objective:</u></i> Patients with atopic dermatitis (AD) experience decreased quality of life (QoL). Here we describe the relationship between severity and QoL-related scores in patients with moderate-to-severe AD treated with dupilumab.</b> <b><i><u>Patients and Methods:</u></i> This was a real-life, retrospective, and observational study involving patients with AD treated with dupilumab. Treatment effectiveness was evaluated based on the changes in the eczema area and severity index (EASI), sleep quality numerical rating scale ,and pruritus numerical rating scale (PNRS), as well as the dermatology life quality index (DLQI). The relationship between each of them was analyzed. After the first data collection at baseline, patients were re-evaluated at 3 subsequent follow-ups (4, 8, and 12 months).</b> <b><i><u>Results:</u></i> A total of 52 patients were enrolled in the study. At 4 months, the change in DLQI is more correlated with PNRSs (<i>r</i> = 0.643, <i>P</i> < 0.001) than the other scores considered. At 8 months, however, the change in DLQIs correlates similarly both with PNRSs (<i>r</i> = 0.644, <i>P</i> < 0.001) and with the change in EASIs (<i>r</i> = 0.633, <i>P</i> < 0.001). At 12 months of treatments, however, the trend reverses and the correlation with EASIs becomes higher (<i>r</i> = 0.735, <i>P</i> < 0.001) than PNRSs (<i>r</i> = 0.0.659, <i>P</i> < 0.001).</b> <b><i><u>Conclusions:</u></i> The results of our study show that the reduction in the impact on QoL for AD patients in the first months of therapy with dupilumab correlates more with the control of pruritus than with the disappearance of skin lesions.</b></p>","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":" ","pages":"440-444"},"PeriodicalIF":4.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Exploring the Relationship Between Dermatology Life Quality Index, Eczema Area and Severity Index, and Sleep Numerical Rating Scale and Pruritus Numerical Rating Scale in Patients with Atopic Dermatitis Treated with Dupilumab.\",\"authors\":\"Filomena Russo,&nbsp;Vittoria Cioppa,&nbsp;Alessandra Cartocci,&nbsp;Ernesto De Piano,&nbsp;Paolo Taddeucci,&nbsp;Laura Lazzeri,&nbsp;Francesco Santi,&nbsp;Pietro Rubegni\",\"doi\":\"10.1089/derm.2022.0031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i><u>Objective:</u></i> Patients with atopic dermatitis (AD) experience decreased quality of life (QoL). Here we describe the relationship between severity and QoL-related scores in patients with moderate-to-severe AD treated with dupilumab.</b> <b><i><u>Patients and Methods:</u></i> This was a real-life, retrospective, and observational study involving patients with AD treated with dupilumab. Treatment effectiveness was evaluated based on the changes in the eczema area and severity index (EASI), sleep quality numerical rating scale ,and pruritus numerical rating scale (PNRS), as well as the dermatology life quality index (DLQI). The relationship between each of them was analyzed. After the first data collection at baseline, patients were re-evaluated at 3 subsequent follow-ups (4, 8, and 12 months).</b> <b><i><u>Results:</u></i> A total of 52 patients were enrolled in the study. At 4 months, the change in DLQI is more correlated with PNRSs (<i>r</i> = 0.643, <i>P</i> < 0.001) than the other scores considered. At 8 months, however, the change in DLQIs correlates similarly both with PNRSs (<i>r</i> = 0.644, <i>P</i> < 0.001) and with the change in EASIs (<i>r</i> = 0.633, <i>P</i> < 0.001). At 12 months of treatments, however, the trend reverses and the correlation with EASIs becomes higher (<i>r</i> = 0.735, <i>P</i> < 0.001) than PNRSs (<i>r</i> = 0.0.659, <i>P</i> < 0.001).</b> <b><i><u>Conclusions:</u></i> The results of our study show that the reduction in the impact on QoL for AD patients in the first months of therapy with dupilumab correlates more with the control of pruritus than with the disappearance of skin lesions.</b></p>\",\"PeriodicalId\":11047,\"journal\":{\"name\":\"Dermatitis\",\"volume\":\" \",\"pages\":\"440-444\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatitis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/derm.2022.0031\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatitis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/derm.2022.0031","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 3

摘要

目的:特应性皮炎(AD)患者生活质量下降。在这里,我们描述了接受dupilumab治疗的中重度AD患者的严重程度与生活质量相关评分之间的关系。患者和方法:这是一项真实的、回顾性的、观察性的研究,涉及接受dupilumab治疗的AD患者。根据湿疹面积和严重程度指数(EASI)、睡眠质量数值评定量表、瘙痒数值评定量量表(PNRS)以及皮肤科生活质量指数(DLQI)的变化来评估治疗效果。分析了它们之间的关系。在基线第一次收集数据后,在随后的3次随访(4个月、8个月和12个月)中对患者进行重新评估。结果:共有52名患者被纳入研究。在4个月时,DLQI的变化与PNRS更相关(r = 0.643,P<0.001)。然而,在8个月时,DLQIs的变化与PNRS相似(r = 0.644,P<0.001)和EASI的变化(r = 0.633,P<0.001)。然而,在治疗12个月时,趋势逆转,并且与EASI的相关性变得更高(r = 0.735,P<0.001)高于PNRS(r = 0.0.659,P<0.001)。结论:我们的研究结果表明,在杜匹单抗治疗的前几个月,AD患者生活质量影响的减少与瘙痒的控制有关,而与皮肤病变的消失有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring the Relationship Between Dermatology Life Quality Index, Eczema Area and Severity Index, and Sleep Numerical Rating Scale and Pruritus Numerical Rating Scale in Patients with Atopic Dermatitis Treated with Dupilumab.

Objective: Patients with atopic dermatitis (AD) experience decreased quality of life (QoL). Here we describe the relationship between severity and QoL-related scores in patients with moderate-to-severe AD treated with dupilumab. Patients and Methods: This was a real-life, retrospective, and observational study involving patients with AD treated with dupilumab. Treatment effectiveness was evaluated based on the changes in the eczema area and severity index (EASI), sleep quality numerical rating scale ,and pruritus numerical rating scale (PNRS), as well as the dermatology life quality index (DLQI). The relationship between each of them was analyzed. After the first data collection at baseline, patients were re-evaluated at 3 subsequent follow-ups (4, 8, and 12 months). Results: A total of 52 patients were enrolled in the study. At 4 months, the change in DLQI is more correlated with PNRSs (r = 0.643, P < 0.001) than the other scores considered. At 8 months, however, the change in DLQIs correlates similarly both with PNRSs (r = 0.644, P < 0.001) and with the change in EASIs (r = 0.633, P < 0.001). At 12 months of treatments, however, the trend reverses and the correlation with EASIs becomes higher (r = 0.735, P < 0.001) than PNRSs (r = 0.0.659, P < 0.001). Conclusions: The results of our study show that the reduction in the impact on QoL for AD patients in the first months of therapy with dupilumab correlates more with the control of pruritus than with the disappearance of skin lesions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Dermatitis
Dermatitis 医学-皮肤病学
CiteScore
5.30
自引率
11.50%
发文量
251
审稿时长
>12 weeks
期刊介绍: Dermatitis is owned by the American Contact Dermatitis Society and is the home journal of 4 other organizations, namely Societa Italiana di Dermatologica Allergologica Professionale e Ambientale, Experimental Contact Dermatitis Research Group, International Contact Dermatitis Research Group, and North American Contact Dermatitis Group. Dermatitis focuses on contact, atopic, occupational, and drug dermatitis, and welcomes manuscript submissions in these fields, with emphasis on reviews, studies, reports, and letters. Annual sections include Contact Allergen of the Year and Contact Allergen Alternatives, for which papers are chosen or invited by the respective section editor. Other sections unique to the journal are Pearls & Zebras, Product Allergen Watch, and news, features, or meeting abstracts from participating organizations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信